HIGHLIGHTS
- who: Francesca Ragusa et al. from the Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa have published the Article: Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer, in the Journal: (JOURNAL) of 18/05/2022
- what: The study reported, (a) in ATC, a median OS of 5.0 months and PFS of 2.8 months; and_(b) in MTC, an objective response rate of 25% and disease control rate in 75%. [62] PTC A total of 14/184 patients had PTC, and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.